Related Experiment Videos
A streptavidin-biotin binding system that minimizes blocking by endogenous biotin
Kevin J Hamblett1, Brian B Kegley, Don K Hamlin
1Department of Bioengineering, University of Washington, Seattle 98195, USA.
Bioconjugate Chemistry
|May 16, 2002
Summary
Researchers developed a mutant streptavidin and bivalent biotin to overcome challenges in pretargeted radioimmunotherapy and diagnostics caused by endogenous biotin. This strategy prevents serum biotin from blocking therapeutic delivery and improving assay sensitivity.
Area of Science:
- Bioconjugation Chemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- Pretargeted radioimmunotherapy utilizes antibody-streptavidin conjugates and radiolabeled biotin for targeted tumor radiation.
- Endogenous biotin in serum can interfere by blocking streptavidin-binding sites, reducing therapeutic efficacy and diagnostic sensitivity.
- The strong biotin-streptavidin interaction makes endogenous biotin a persistent issue in these applications.
Purpose of the Study:
- To investigate a novel approach using a streptavidin mutant (SAv-Y43A) and bivalent biotin constructs to counteract endogenous biotin interference.
- To engineer and evaluate bivalent biotin molecules with improved properties for use in pretargeting strategies.
- To assess the binding kinetics and retention of these novel constructs compared to wild-type biotin.
Main Methods:
- A streptavidin mutant (SAv-Y43A) with reduced biotin affinity was employed.
- Three bivalent bis-biotin constructs were designed with considerations for solubility, stability, and linker length.
- Binding assays, including exchange, retention, and off-rate studies, were performed to compare bivalent biotins with standard biotin.
- Fluorescent competition experiments were used to evaluate avidity and retention.
Main Results:
- The SAv-Y43A mutant facilitated efficient exchange of prebound biotin by the bivalent biotin dimers.
- Bivalent biotin ligands demonstrated high avidity and near-irreversible binding to SAv-Y43A.
- A biotinidase-stabilized biotin dimer exhibited an off-rate over 640 times slower than biotin, indicating enhanced retention.
Conclusions:
- The combination of SAv-Y43A and bivalent biotin effectively mitigates the negative impact of endogenous serum biotin.
- This approach shows significant promise for enhancing the efficacy of pretargeted radioimmunotherapy and improving the sensitivity of diagnostic assays.
- The developed system offers a robust solution for overcoming biotin interference in targeted molecular delivery systems.